首頁 > 市場調查報告書 > 製藥

精神疾病

猝睡症市場:1次調查(KOL的洞察) - 市場情報 - 流行病學和至2032年的市場預測

市場調查報告書

商品編碼

1170394

猝睡症市場:1次調查(KOL的洞察) - 市場情報 - 流行病學和至2032年的市場預測

Narcolepsy| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032

出版日期: 2022年09月07日 | 出版商:

Mellalta Meets LLP | 英文 217 Pages | 訂單完成後即時交付

價格

簡介目錄

全球猝睡症治療藥的市場規模，2018年～至2032年，預計以7.8％的年複合成長率" 擴大，至2032年達到50億美元。

本報告提供全球猝睡症市場相關調查，市場現狀，以及病例數趨勢，患者趨勢，競爭產品的市場上地位，市場機會等資訊。

The Narcolepsy market is hugely contributed by a very narrow range of treatment options available and only limited to the management of the symptoms. But currently, no medicine can cure Narcolepsy completely. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a NARCOLEPSY treatment setting, the current SoC will increase along with the launch and uptake of novel emerging drugs while will drive market shares. The sales of the emerging therapies for the treatment of Narcolepsy in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5 billion by 2032.

"For decades, patients with narcolepsy have complained of depressive symptoms. In addition, the presence of [a] clinically defined major depressive episode, suicidal thoughts, and suicide risks have been seldom investigated in NT1, although sleep disturbances are often associated with suicidality".

Narcolepsy is a chronic neurological disorder that affects the brain's ability to control sleep-wake cycles. People with narcolepsy may feel rested after waking, but then feel very sleepy throughout much of the day. Many individuals with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night. Narcolepsy affects both males and females equally. Symptoms often start in childhood, adolescence, or young adulthood (ages 7 to 25), but can occur at any time in life.

Narcolepsy - Epidemiology

The total NARCOLEPSY prevalent cases in the G7 countries are anticipated to increase to 557,552 cases by 2032 for the study period (2018- 2032). As per estimates, Japan accounted for the highest prevalence of Narcolepsy cases in 2018 which was 212,004 cases and is expected to increase by 2032 for the study period. Among the EU5, Germany had the highest Narcolepsy cases, followed by the UK, France, Italy, and Spain. The United States is reported to have the highest number of treated cases after Japan, Germany, and the UK.

Current treatments for narcolepsy are currently aimed at controlling the principal symptoms: EDS, cataplexy, sleep fragmentation, sleep paralysis, and hypnagogic and hypnopompic hallucinations, but are not intended to cure the disease. However, the treatment does manage to significantly improve the quality of life.

Narcolepsy - Current Market Size & Forecast Trends

The Narcolepsy therapeutics market is expected to experience high growth throughout our study period (i.e., 2018 to 2032) to USD 5 billion, representing compound annual growth (CAGR) of 7.8%.

The United States captured the highest market share in 2022 as compared to the European 5 countries and Japan. The increase in the diagnosis rate and the usage of the current standard of care for controlling the symptoms will drive the therapeutic market for narcolepsy. By 2032, the market share of the United States is expected to increase to USD 4 billion whereas European 5 countries and Japan will have USD XX billion and USD XX million market size in 2032, respectively.

Despite the progress in the understanding of mechanisms underlying this condition, there is currently no cure for narcolepsy. Available drugs are all symptomatic therapies and cannot change the pathophysiologic course of the disease. More than 90% of patients with narcolepsy require pharmacological treatment, usually needed lifelong.

The majority of patients receiving narcolepsy-related pharmacological therapy were treated with modafinil, which is a recommended first-line medication option for narcolepsy. These drugs that stimulate the central nervous system are the primary treatment to help people with narcolepsy stay awake during the day. The demand for stimulants and selective serotonin to manage narcolepsy will dominate the global narcolepsy drugs market in the begging.

In the 2018-2032 forecast period, we expect that with the launch of the new therapies, the current treatment landscape will expand, catering to the need for treatment of cataplexy, abnormal hallucinations or dream-like experiences, and excessive daytime sleepiness (EDS) associated with narcolepsy patients. The emerging therapies which are expected to enter the market from 2022-2032 period are LUMRYZ/Sodium oxybate (Avadel Pharmaceuticals), Reboxetine (Axsome Therapeutics, Inc.), Quilience/Mazindol extended release (NLS Pharmaceutics Ltd) and Samelisant (Suven Life Sciences).

Report Highlights

Narcolepsy - Current Market Trends

Narcolepsy - Current & Forecasted Cases across the G7 Countries

Narcolepsy - Market Opportunities and Sales Potential for Agents

Narcolepsy - Patient-based Market Forecast to 2032

Narcolepsy - Untapped Business Opportunities

Narcolepsy - Product Positioning Vis-a-vis Competitors' Products

Narcolepsy - KOLs Insight

Executive Summary

Key Findings

Narcolepsy Disease Background

Narcolepsy Definition
Symptoms & Causes
Pathophysiology
Diagnosis

Epidemiology Estimated and Forecast to 2032

Key Findings
Methods and data Sources
- Country Specific Prevalent cases of Narcolepsy (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Drug Treated Cases of Narcolepsy
- United States
  - United States Prevalent cases of Narcolepsy
  - United States Drug Treated Cases of Narcolepsy

Key Sources for Narcolepsy Epidemiology and Model Parameters

Germany
- Germany Prevalent cases of Narcolepsy
- Germany Drug Treated Cases of Narcolepsy
France
- France Prevalent cases of Narcolepsy
- France Drug Treated Cases of Narcolepsy
Italy
- Italy Prevalent cases of Narcolepsy
- Italy Drug Treated Cases of Narcolepsy
Spain
- Spain Prevalent cases of Narcolepsy
- Spain Drug Treated Cases of Narcolepsy
United Kingdom
- United Kingdom Prevalent cases of Narcolepsy
- United Kingdom Drug Treated Cases of Narcolepsy
Japan
- Japan Prevalent cases of Narcolepsy
- Japan Drug Treated Cases of Narcolepsy

Current Therapies and Medical Practice

Treatments & Medical Practices

Marketed Therapies

Product Analysis
- Provigil/Modafinil (Cephalon/Teva)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032
- Xyrem/Gamma-hydroxybutyrate (Jazz Pharma)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032
- Nuvigil/Armodafinil (Cephalon/Teva Branded Pharmaceutical Products R&D, Inc.)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032
- Wakix/Pitolisant (Bioprojet/ Harmony Biosciences)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032
- Sunosi/Solriamfetol (Jazz/SK Biopharma)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032
- Xywav/Sodium oxybate (Jazz Pharma)
  - Product Profile
  - Clinical Development
  - Sales & Market Opportunity by 2032

Unmet Needs

Emerging Therapies

Pipeline Overview
Therapeutic Developments Pipeline for Narcolepsy
- Product Analysis
  - Lumryz/Sodium Oxybate (Avadel Pharmaceuticals)
    - Product Profile
    - Clinical Development
    - Sales & Market Opportunity by 2032
  - Reboxetine (Axsome Therapeutics, Inc.)
    - Product Profile
    - Clinical Development
    - Sales & Market Opportunity by 2032
  - Samelisant (Suven Life Sciences)
    - Product Profile
    - Clinical Development
  - Mazindol (NLS Pharmaceutics Ltd)
    - Product Profile
    - Clinical Development
  - Pentetrazol (Balance Therapeutics)
    - Product Profile
    - Clinical Development
  - Ulotaront (Sunovion)
    - Product Profile
    - Clinical Development
  - Danavorexton (Takeda)
    - Product Profile
    - Clinical Development
  - TAK-861 (Takeda)
    - Product Profile
  - DSP 0187 (Sumitomo Dainippon Pharma)
    - Product Profile
    - Clinical Development
  - ADAIR (Abuse-deterrent formulation of immediate-release (IR) dextroamphetamine) (Vallon Pharma)
    - Product Profile
    - Clinical Development
  - Valiloxybate (XWPharma)
    - Product Profile

Narcolepsy- Reimbursement Scenario

Narcolepsy- Cost Burden & Prescriptions survey

Future Treatment Paradigm

Narcolepsy Competitor Landscape and Approvals Anticipated
Future Treatment Algorithms and Competitor Positioning
Key Data Summary for Emerging Treatment
Competitive Landscape of Narcolepsy
Phase III and Pivotal Phase II Drugs Clinical & Regulatory Timeline in Narcolepsy

Annual Cost of Current & Emerging Therapies

Market Outlook

Key Findings
Country Specific Market Forecast to 2032
- G7 total Market for Narcolepsy 2018-2032 (USD Million)
- G7 total Market for Narcolepsy by Therapies 2018-2032 (USD Million)

Market Forecast by Country

United States
- United States Market for Narcolepsy 2018-2032 (USD Million)
- United States Market for Narcolepsy by Therapies 2018-2032 (USD Million)

Market Forecast by Country

Germany
- Germany Market for Narcolepsy 2018-2032 (USD Million)
- Germany Market for Narcolepsy by Therapies 2018-2032 (USD Million)
France
- France Market for Narcolepsy 2018-2032 (USD Million)
- France Market for Narcolepsy by Therapies 2018-3032 (USD Million)
Italy
- Italy Market for Narcolepsy 2018-2032 (USD Million)
- Italy Market for Narcolepsy by Therapies 2018-2032 (USD Million)
Spain
- Spain Market for Narcolepsy 2018-2032 (USD Million)
- Spain Market for Narcolepsy by Therapies 2018-2032 (USD Million)
United Kingdom
- United Kingdom Market for Narcolepsy 2018-2032 (USD Million)
- United Kingdom Market for Narcolepsy by Therapies 2018-2032 (USD Million)
Japan
- Japan Market for Narcolepsy 2018-2032 (USD Million)
- Japan Market for Narcolepsy by Therapies 2018-2032 (USD Million)